Xiaobao Yang

9PUBLICATIONS
30CO-AUTHORS
Cell development, proliferation and deathHaematological tumoursMolecular targetsGene and molecular therapyProteomics and metabolomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Dec 18, 2024
Minimizing DNA trapping while maintaining activity inhibition via selective PARP1 degrader.

Li Chen, Yahui Zou, Renhong Sun

|Dec 05, 2024
CDK9 recruits HUWE1 to degrade RARĪ± and offers therapeutic opportunities for cutaneous T-cell lymphoma.

Chen-Hui Luo, Li-Hong Hu, Jie-Yang Liu

|Oct 22, 2024
Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR-ABL-Positive Leukemia.

Ziwei Luo, Chencen Lin, Chuwei Yu

|Nov 30, 2022
Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets.

Yan Xiong, Yue Zhong, Hyerin Yim

|Nov 22, 2022
DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs.

Fenglei Li, Qiaoyu Hu, Xianglei Zhang

|Sep 27, 2021
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders.

Xuewei Wu, Xiaobao Yang, Yan Xiong

Pageof 2

Frequent Collaborators

2 joint publications

Jian Jin

1 joint publications

Li Xia

1 joint publications

Xue-Hong Zhang

1 joint publications

Guo-Qiang Chen